Jasper Therapeutics Announces Plans for Registrational Study of JSP191 in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation after Type C FDA MeetingGlobeNewsWire • 04/28/22
Jasper Therapeutics Announces Updated Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell TransplantationGlobeNewsWire • 04/26/22
Jasper Therapeutics to Present Updated Data on JSP191 Conditioning in SCID Patients at the 2022 Clinical Immunology Society Annual MeetingGlobeNewsWire • 03/31/22
Jasper Therapeutics Announces Management Changes to Strengthen Leadership TeamGlobeNewsWire • 03/21/22
Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 03/18/22
Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare ConferenceGlobeNewsWire • 03/10/22
Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive OfficerGlobeNewsWire • 02/28/22
Jasper Therapeutics Announces JSP191 Phase 1b MDS/AML Late Breaking Data Presentation at the 2022 Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTRGlobeNewsWire • 02/24/22
12 biotech stocks to consider buying now as prospects for the sector brighten this yearMarket Watch • 02/06/22
Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual MeetingGlobeNewsWire • 12/08/21
Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior ConditioningSeeking Alpha • 11/28/21
Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 11/12/21
Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare ConferenceGlobeNewsWire • 11/08/21
JSPR Stock: The Bullish Call That Has Biotech Play Jasper Therapeutics Rocketing 105% TodayInvestorPlace • 10/13/21
Jasper Therapeutics' stock more than doubles after Oppenheimer analyst's bullish callMarket Watch • 10/13/21